Comparison of the efficacy and safety profiles of generic and branded leuprorelin acetate microspheres in patients with prostate cancer

Zhou,Zhien; Zhou,Yi; Yan,Weigang; Feng,Tianrui; Liang,Zhen

doi:10.3892/ol.2024.14452

Comparison of the efficacy and safety profiles of generic and branded leuprorelin acetate microspheres in patients with prostate cancer

Authors:
- Zhien Zhou
- Yi Zhou
- Weigang Yan
- Tianrui Feng
- Zhen Liang
View Affiliations

Affiliations: Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China
Published online on: May 14, 2024 https://doi.org/10.3892/ol.2024.14452
Article Number: 319

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Leuprorelin acetate microspheres, a common gonadotropin‑releasing hormone agonist, have certain clinical benefits for prostate cancer (PCa). The present study aimed to compare the efficacy and safety of generic and branded leuprorelin acetate microspheres in patients with PCa. The present retrospective, observational study included 116 patients with PCa who received generic (Boennuokang®; Beijing Biote Pharmaceutical Co., Ltd.) or branded (Enantone®; Takeda Pharmaceutical Company, Ltd.) leuprorelin acetate microspheres via injection (commonly 3.75 mg once every 4 weeks), defined as the test (n=64) and reference (n=52) groups, respectively. The present study showed that testosterone levels at month (M) 3 (P<0.001), M6 (P=0.012) and M12 (P<0.001) were decreased in the test group compared with the reference group. However, prostate‑specific antigen (PSA) levels at baseline, M1, M3, M6 and M12 were not significantly different between the test and reference groups (all P>0.05). The median (interquartile range) testosterone and PSA levels at M12 were 15.50 ng/dl (10.00‑31.25 ng/dl) and 0.01 ng/ml (0.01‑0.10 ng/ml), respectively, in the test group and 28.00 ng/dl (22.00‑37.00 ng/dl) and 0.02 ng/ml (0.01‑0.16 ng/ml), respectively, in the reference group. No significant differences were observed in the M1‑baseline, M3‑baseline, M6‑baseline and M12‑baseline changes of testosterone or PSA levels between the two groups (all P>0.050). Additionally, the incidence of all adverse events was not significantly different between the two groups (all P>0.050). Overall, Boennuokang® leuprorelin acetate microspheres exhibited a similar efficacy for suppression of testosterone and PSA levels with a comparable safety profile compared with Enantone® leuprorelin acetate microspheres in patients with PCa.

View Figures

View References

1	Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T and Bristow RG: Prostate cancer. Nat Rev Dis Primers. 7:92021. View Article : Google Scholar : PubMed/NCBI
2	Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A and Mashele S: Prostate cancer review: Genetics, diagnosis, treatment options, and alternative approaches. Molecules. 27:57302022. View Article : Google Scholar : PubMed/NCBI
3	Sun D, Li H, Cao M, He S, Lei L, Peng J and Chen W: Cancer burden in China: Trends, risk factors and prevention. Cancer Biol Med. 17:879–895. 2020. View Article : Google Scholar : PubMed/NCBI
4	Qiu H, Cao S and Xu R: Cancer incidence, mortality, and burden in China: A time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 41:1037–1048. 2021. View Article : Google Scholar : PubMed/NCBI
5	Williams IS, McVey A, Perera S, O'Brien JS, Kostos L, Chen K, Siva S, Azad AA, Murphy DG, Kasivisvanathan V, et al: Modern paradigms for prostate cancer detection and management. Med J Aust. 217:424–433. 2022. View Article : Google Scholar : PubMed/NCBI
6	Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, et al: EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol. 79:243–262. 2021. View Article : Google Scholar : PubMed/NCBI
7	Desai K, McManus JM and Sharifi N: Hormonal therapy for prostate cancer. Endocr Rev. 42:354–373. 2021. View Article : Google Scholar : PubMed/NCBI
8	Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, Miller K, Debruyne FMJ and Klotz L: Androgen-targeted therapy in men with prostate cancer: Evolving practice and future considerations. Prostate Cancer Prostatic Dis. 22:24–38. 2019. View Article : Google Scholar : PubMed/NCBI
9	Zhu Y, Mo M, Wei Y, Wu J, Pan J, Freedland SJ, Zheng Y and Ye D: Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol. 18:282–301. 2021. View Article : Google Scholar : PubMed/NCBI
10	Iwamoto H, Izumi K, Makino T and Mizokami A: Androgen deprivation therapy in high-risk localized and locally advanced prostate cancer. Cancers (Basel). 14:18032022. View Article : Google Scholar : PubMed/NCBI
11	Yu EM and Aragon-Ching JB: Advances with androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother. 23:1015–1033. 2022. View Article : Google Scholar : PubMed/NCBI
12	Merseburger AS, Hammerer P, Rozet F, Roumeguère T, Caffo O, da Silva FC and Alcaraz A: Androgen deprivation therapy in castrate-resistant prostate cancer: How important is GnRH agonist backbone therapy? World J Urol. 33:1079–1085. 2015. View Article : Google Scholar : PubMed/NCBI
13	Raja T, Sud R, Addla S, Sarkar KK, Sridhar PS, Talreja V, Jain M and Patil K: Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety. Indian J Cancer. 59:S142–S159. 2022. View Article : Google Scholar : PubMed/NCBI
14	Persad R: Leuprorelin: A leading role in advanced prostate cancer therapy. Hosp Med. 64:360–363. 2003. View Article : Google Scholar : PubMed/NCBI
15	Wilson AC, Meethal SV, Bowen RL and Atwood CS: Leuprolide acetate: A drug of diverse clinical applications. Expert Opin Investig Drugs. 16:1851–1863. 2007. View Article : Google Scholar : PubMed/NCBI
16	Shim M, Bang WJ, Oh CY, Lee YS and Cho JS: Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide. Investig Clin Urol. 60:244–250. 2019. View Article : Google Scholar : PubMed/NCBI
17	McKay RR, Xie W, Ye H, Fennessy FM, Zhang Z, Lis R, Calagua C, Rathkopf D, Laudone VP, Bubley GJ, et al: Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer. J Urol. 206:80–87. 2021. View Article : Google Scholar : PubMed/NCBI
18	Mizokami A, Ueno S, Fukagai T, Ito K, Ehara H, Kinbara H, Origasa H, Usami M, Namiki M and Akaza H: Global update on defining and treating high-risk localized prostate cancer with leuprorelin: An Asian perspective. BJU Int. 99 (Suppl 1):S6–S9; discussion 17–18. 2007. View Article : Google Scholar
19	Suzuki K, Namiki M, Fujimoto T, Takabayashi N, Kudou K and Akaza H: Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: A phase III, randomized, open-label, parallel-group, comparative study in Japan. Jpn J Clin Oncol. 45:1168–1174. 2015.PubMed/NCBI
20	Chung BH, Horie S and Chiong E: Clinical studies investigating the use of leuprorelin for prostate cancer in Asia. Prostate Int. 8:1–9. 2020. View Article : Google Scholar : PubMed/NCBI
21	Li WL, Shi QB, Han WH and Li CM: Influence on efficacy and immune function in patients with prostate cancer by using intensity-modulated radiotherapy combined with endocrine therapy. Pract J Cancer. 34:1275–1279. 2019.(In Chinese).
22	Su JQ, Xin JH, Zhao XR and Guan MG: The effect of intensity-modulated radiotherapy combined with endocrine therapy on prostate cancer. Guide Chin Med. 5:110–112. 2022.(In Chinese).
23	Ling KN, Yang JR, Li BJ, Li J, Ji ZQ and Liu JZ: A study on the clinical efficacy of medical castration in treatment of prostate cancer complicated with urinary retention. Chin J Clin Med. 15:340–344. 2022.(In Chinese).
24	Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, et al: Prostate cancer, version 1.2016. J Natl Compr Canc Netw. 14:19–30. 2016. View Article : Google Scholar : PubMed/NCBI
25	Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR and Humphrey PA; Grading Committee, : The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: Definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 40:244–252. 2016. View Article : Google Scholar : PubMed/NCBI
26	Wu LX, Lei L, Zhu YC, Du KQ, Li XF, Chen HF, Wang WX and Xu CW: A prostate cancer patient with isolated lung metastases: A case report. Transl Cancer Res. 9:2064–2068. 2020. View Article : Google Scholar : PubMed/NCBI
27	Zhang L, Tao D and Wang S: Clinical evaluation of enantone in the treatment of prostate cancer. Zhonghua Zhong Liu Za Zhi. 19:218–220. 1997.(In Chinese). PubMed/NCBI
28	Padula GD, Zelefsky MJ, Venkatraman ES, Fuks Z, Lee HJ, Natale L and Leibel SA: Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 52:439–443. 2002. View Article : Google Scholar : PubMed/NCBI
29	Marberger M, Kaisary AV, Shore ND, Karlin GS, Savulsky C, Mis R, Leuratti C and Germa JR: Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: A phase III, open-label, international multicenter study. Clin Ther. 32:744–757. 2010. View Article : Google Scholar : PubMed/NCBI
30	George DJ, Saad F, Cookson MS, Saltzstein DR, Tutrone R, Bossi A, Brown B, Selby B, Lu S, Buckley D, et al: Impact of concomitant prostate cancer medications on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer. Clin Genitourin Cancer. 21:383–392. e22023. View Article : Google Scholar : PubMed/NCBI
31	LBA02-09 EMBARK, . A Phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer. J Urol. 210:224–226. 2023. View Article : Google Scholar